Continuous HRT vs Cyclical HRT in Perimenopause: Which Regimen Is Right for You?
Continuous vs cyclical HRT in perimenopause explained. Covers who each suits, bleeding patterns, switching regimens, and pros and cons of both.
Understanding the Two Main HRT Regimens
When a woman with a uterus takes HRT, she needs both oestrogen and a progestogen to protect the uterine lining from the proliferative effects of oestrogen taken alone. The way the progestogen is given defines the regimen: in cyclical (also called sequential) HRT, progestogen is taken for 10 to 14 days each month, followed by a withdrawal bleed. In continuous combined HRT, oestrogen and progestogen are taken every day without a break, which eventually results in no monthly bleed. Oestrogen itself is taken continuously in both regimens. The distinction matters for several reasons: the pattern of progestogen exposure affects bleeding, side effects, and suitability depending on where a woman is in her perimenopause or postmenopause transition. Women who have had a hysterectomy do not need any progestogen and can take oestrogen alone, making the cyclical versus continuous question irrelevant for them. For everyone else, choosing the right regimen involves considering menstrual status, symptom history, progestogen tolerance, and personal preference around bleeding.
Cyclical HRT: Who It Is Designed For
Cyclical HRT is the recommended starting regimen for women who are still having periods or who have had a period within the past year. The monthly progestogen phase mimics the natural hormonal fluctuation of the menstrual cycle and produces a predictable withdrawal bleed at the end of each progestogen phase. This withdrawal bleed is not a true menstrual period but is caused by the drop in progestogen and the subsequent shedding of any endometrium that has built up in response to oestrogen. For women in perimenopause who still have irregular cycles, cyclical HRT can bring order to the hormonal chaos of irregular periods, replacing unpredictable heavy or erratic bleeding with a regular, lighter, and more predictable pattern. Cyclical HRT is also available in three-monthly variants, where progestogen is taken for two weeks every three months, producing four bleeds per year rather than twelve. This can suit women who find monthly bleeds inconvenient but are not yet suitable for continuous HRT. The main limitation of cyclical HRT is that some women experience significant progestogen-related side effects during the 10 to 14 day phase, including low mood, bloating, breast tenderness, and irritability, which closely mirrors the premenstrual symptoms many perimenopausal women are already trying to escape.
Continuous HRT: Who Benefits and When to Switch
Continuous combined HRT is recommended for women who have been postmenopausal for at least one year, meaning they have not had a natural period for twelve months. In continuous HRT, the daily dose of progestogen is lower than in cyclical regimens because it does not need to produce a monthly bleed; instead, it maintains the endometrium in a thin, inactive state. This leads to no scheduled bleeding in the majority of women, though irregular spotting is common in the first three to six months as the uterine lining adjusts. Starting continuous HRT too early, before a woman is confirmed postmenopausal, increases the risk of irregular and unpredictable breakthrough bleeding, which is why timing matters. In practice, many women switch from cyclical to continuous HRT after their last natural period is confirmed, typically somewhere between 12 and 24 months after periods cease. The transition is straightforward and involves simply changing to a combined continuous preparation at the next prescription review. Women who found the cyclical progestogen phase problematic often report that continuous HRT is easier to tolerate because the daily low-dose progestogen does not cause the same fluctuating hormonal effects.
Bleeding Patterns: What to Expect With Each
Managing expectations around bleeding is one of the most practical aspects of HRT counselling. With cyclical HRT, a withdrawal bleed usually occurs in the days after the progestogen phase ends and is typically lighter and more predictable than a natural perimenopause period. Some women find this reassuring; others find the monthly bleed one of the main reasons they want to transition to continuous HRT as soon as possible. With continuous HRT, irregular spotting or light bleeding in the first three to six months is very common and does not indicate a problem with the endometrium. It reflects the uterine lining adjusting to the constant low-dose progestogen environment. After six months on continuous combined HRT, the majority of women are bleed-free. Any bleeding that occurs beyond the first six months, or any heavy or prolonged bleeding at any point, should be assessed by a GP or gynaecologist to exclude endometrial pathology, even though such bleeding is usually benign. An endometrial biopsy or pelvic ultrasound to measure the endometrial thickness is the appropriate investigation. Women should not be alarmed by this investigation: it is a standard safety check rather than an indication that something is wrong.
Progestogen Options Within Each Regimen
The choice of progestogen within a cyclical or continuous regimen significantly affects the experience of HRT. Synthetic progestogens, such as norethisterone, levonorgestrel, and medroxyprogesterone acetate, are effective at protecting the endometrium but carry a higher rate of mood-related side effects and may slightly increase breast cancer risk compared to micronised progesterone. Micronised progesterone (branded as Utrogestan in the UK) is body-identical and has a more favourable side-effect profile, including a calming and sleep-promoting effect for many women. In a cyclical regimen, micronised progesterone is taken at 200 mg per night for 12 consecutive days each month. In a continuous regimen, it is taken at 100 mg per night every night. Continuous micronised progesterone is not formally licensed in the UK for endometrial protection in this way, but it is widely used off-label by menopause specialists based on good evidence that the daily 100 mg dose provides adequate protection. Combined patches such as Evorel Conti (continuous) and Evorel Sequi (cyclical) offer a progestogen-containing option for women who prefer not to take oral tablets, using norgestimate, which has a relatively favourable metabolic profile among the synthetic progestogens.
Making the Decision: Key Questions to Guide Your Choice
Choosing between cyclical and continuous HRT involves answering a few practical questions. The first is whether periods have stopped for at least 12 months: if yes, continuous HRT is appropriate; if no, cyclical is the starting point. The second is how much monthly bleeding matters as a quality-of-life issue: women for whom any bleed is unacceptable may want to discuss whether their situation is close enough to confirmed postmenopause to attempt an early transition to continuous HRT, accepting that breakthrough bleeding may be more likely. The third question is how well progestogen has been tolerated in the past, including any experience of PMS or progestogen-related mood symptoms: women with a history of significant progestogen sensitivity may benefit from micronised progesterone over synthetic options regardless of which regimen they use. The fourth question is practicality: patch regimens, combined pill-type preparations, and separate oestrogen plus oral progestogen all have slightly different logistics, and choosing what fits best into daily routines supports long-term adherence. Reviewing the regimen at three to six month intervals in the first year allows dose adjustments and progestogen changes to optimise the experience without unnecessary delays.
Related reading
Get your personalized daily plan
Track symptoms, match workouts to your day type, and build a routine that adapts with you through every phase of perimenopause.